[1]
D. Buenaventura Collazos, C. Aguilar Londoño, N. Aristizábal-Henao, J. Torres-Grajales, and J. Gutiérrez-Restrepo, “Lenvatinib dose-escalation therapy in a patient with papillary thyroid carcinoma after discontinuation due to a severe adverse event ”, Rev.ACE, vol. 12, no. 2, Jun. 2025.